WallStSmart
ENLV

Enlivex Therapeutics Ltd

NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY

$0.73
-1.56% today

Updated 2026-06-02

Market cap
$171.15M
P/E ratio
0.03
P/S ratio
EPS (TTM)
$25.48
Dividend yield
52W range
$1 – $2
Volume
0.7M

Enlivex Therapeutics Ltd (ENLV) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20022003200420052006200720122013201420152016201720182019202020212022202320242025
Operating cash flow$-149000.00$-865000.00$-4.41M$-13.25M$-15.49M$-6.35M$-3.16M$-7.04M$-11.01M$-17.54M$-23.95M$-23.52M$-13.01M$-10.42M
Capital expenditures$936000.00$461000.00$418000.00$389000.00$450000.00$664000.00$0.00$2000.00$63000.00$48000.00$18000.00$2000.00$461000.00$193000.00$1.02M$1.63M$8.12M$236000.00$103000.00$68000.00
Depreciation
Stock-based comp$9000.00$254000.00$736000.00$2.62M$700000.00$408000.00$1.01M$810000.00$670000.00$2.91M$2.71M$1.95M$2.06M$1.78M
Free cash flow$-149000.00$-867000.00$-4.47M$-13.30M$-15.50M$-6.35M$-3.62M$-7.23M$-12.03M$-19.17M$-32.08M$-23.76M$-13.11M$-10.48M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

How much free cash flow does ENLV generate?

ENLV produced $-10.48M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ENLV's balance sheet healthy?

ENLV holds $2.01M in cash and equivalents against — in long-term debt, on $1.93B of shareholder equity. That debt is best read against the cash flow the business throws off each year.